COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S. Fulda; Kathleen V. Fitch; Edgar T. Overton; Markella V. Zanni; Judith A. Aberg; Judith S. Currier; Michael T. Lu; Carlos Malvestutto; Carl J. Fichtenbaum; Esteban Martinez; Triin Umbleja; Pamela S. Douglas; Heather J. Ribaudo; Steven K. Grinspoon

doi:10.1093/infdis/jiab575

COVID-19 Vaccination Rates in a Global HIV Cohort

Evelynne S. Fulda, Kathleen V. Fitch, Edgar T. Overton, Markella V. Zanni, Judith A. Aberg, Judith S. Currier, Michael T. Lu, Carlos Malvestutto, Carl J. Fichtenbaum, Esteban Martinez, Triin Umbleja, Pamela S. Douglas, Heather J. Ribaudo, Steven K. Grinspoon

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.

Original language	English
Pages (from-to)	603-607
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	225
Issue number	4
DOIs	https://doi.org/10.1093/infdis/jiab575
State	Published - 15 Feb 2022

Keywords

COVID-19
Global Burden of Disease region
Human immunodeficiency virus
Vaccination

Access to Document

10.1093/infdis/jiab575

Cite this

@article{652c1b7046f84f9d86bf5a64ccf3e43c,

title = "COVID-19 Vaccination Rates in a Global HIV Cohort",

abstract = "Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.",

keywords = "COVID-19, Global Burden of Disease region, Human immunodeficiency virus, Vaccination",

author = "Fulda, {Evelynne S.} and Fitch, {Kathleen V.} and Overton, {Edgar T.} and Zanni, {Markella V.} and Aberg, {Judith A.} and Currier, {Judith S.} and Lu, {Michael T.} and Carlos Malvestutto and Fichtenbaum, {Carl J.} and Esteban Martinez and Triin Umbleja and Douglas, {Pamela S.} and Ribaudo, {Heather J.} and Grinspoon, {Steven K.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s) 2021.",

year = "2022",

month = feb,

day = "15",

doi = "10.1093/infdis/jiab575",

language = "English",

volume = "225",

pages = "603--607",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - COVID-19 Vaccination Rates in a Global HIV Cohort

AU - Fulda, Evelynne S.

AU - Fitch, Kathleen V.

AU - Overton, Edgar T.

AU - Zanni, Markella V.

AU - Aberg, Judith A.

AU - Currier, Judith S.

AU - Lu, Michael T.

AU - Malvestutto, Carlos

AU - Fichtenbaum, Carl J.

AU - Martinez, Esteban

AU - Umbleja, Triin

AU - Douglas, Pamela S.

AU - Ribaudo, Heather J.

AU - Grinspoon, Steven K.

PY - 2022/2/15

Y1 - 2022/2/15

N2 - Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.

AB - Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk.

KW - COVID-19

KW - Global Burden of Disease region

KW - Human immunodeficiency virus

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85124634431&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiab575

DO - 10.1093/infdis/jiab575

M3 - Article

C2 - 34794178

AN - SCOPUS:85124634431

SN - 0022-1899

VL - 225

SP - 603

EP - 607

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 4

ER -

COVID-19 Vaccination Rates in a Global HIV Cohort

Abstract

Keywords

Access to Document

Fingerprint

Cite this